On September 3, the 21st China International Small and Medium Enterprises Expo (CISMEF), themed “Empowering SMEs with Artificial Intelligence,” opened in Guangzhou. Zhang Guoqing, a member of the Political Bureau of the CPC Central Committee and Vice Premier of the State Council, and Huang Kunming, a member of the Political Bureau of the CPC Central Committee and Secretary of the CPC Guangdong Provincial Committee, attended the opening ceremony and delivered remarks. At the expo, the 15th Five-Year Plan for Promoting the Development of Small and Medium Enterprises was released. The plan calls for stronger policy support, deeper reform and innovation, greater internal vitality and competitiveness among enterprises, and further development of SMEs toward specialization and innovation. As a national-level expo hosted by the Ministry of Industry and Information Technology, CISMEF has long focused on the innovation and development of SMEs. It aims to build a global showcase for Chinese SMEs, promote the application of new technologies, business models, and emerging forms of business, and help SMEs better integrate into global industrial and supply chains. <img src="/uploaded/accumedical/news/content/2026/09/21/oe8yjuripc.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/oe8yjuripc.png" style="width: 50%;">The 21st China International Small and Medium Enterprises Expo This year, the Beijing Municipal Bureau of Economy and Information Technology selected 15 high-quality enterprises from across Beijing to participate in the expo, showcasing the latest achievements of Beijing-based SMEs in technological innovation, industrial upgrading, and high-quality development. This year, the Beijing Municipal Bureau of Economy and Information Technology selected 15 high-quality enterprises from across Beijing to participate in the expo, showcasing the latest achievements of Beijing-based SMEs in technological innovation, industrial upgrading, and high-quality development. AccuMedical Inc., the only neurointerventional medical device company selected to participate, showcased its proprietary innovative solutions at the expo, demonstrating the technological capabilities and development achievements of Beijing’s innovative medical device enterprises. <img src="/uploaded/accumedical/news/content/2026/09/21/vwc93ru89ws.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/vwc93ru89ws.png" style="width: 50%;">Visitors from various sectors at the AccuMedical boothAs an innovative medical device company specializing in neurointervention and integrating R&amp;D, manufacturing, and commercialization capabilities, AccuMedical has consistently focused on unmet clinical needs in the field of cerebrovascular diseases. The company continues to advance technological innovation in the treatment of hemorrhagic and ischemic stroke, providing innovative solutions for physicians and patients with cerebrovascular diseases worldwide. To date, 10 AccuMedical products have received NMPA approval, including the Lattice® Flow Diverter series, Grism® Stent Retriever, Attractor® Aspiration Catheter, Cosine® Distal Access Catheter series, and Sine® Microcatheter series. These products represent substantive innovation in the high-end neurointerventional medical device sector, a key area of national focus. Meanwhile, several of AccuMedical’s core products have obtained regulatory approvals or market access in overseas markets, including the European Union under the MDR, the United States through the FDA, Vietnam, and Indonesia, further advancing the global expansion of Chinese proprietary medical devices. <img src="/uploaded/accumedical/news/content/2026/09/21/1dk19vdvi84.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/1dk19vdvi84.png" style="width: 50%;">AccuMedical booth at the 21st China International Small and Medium Enterprises ExpoAt the expo, AccuMedical highlighted innovative solutions for both hemorrhagic and ischemic stroke.In the field of hemorrhagic stroke, AccuMedical showcased its internationally advanced solution for the treatment of intracranial aneurysms—the Lattice® Flow Diverter series. Since receiving marketing approval, the product has achieved a 21% market share in China[1], with more than 14,000 implants cumulatively as of the end of 2025. Supported by robust product performance, multiple key clinical datasets[2] have demonstrated significantly better performance than comparable products from traditional international brands, highlighting the innovation and competitiveness of China’s domestically developed neurointerventional devices. According to the latest real-world study presented at the American Stroke Association’s International Stroke Conference (ISC) in 2026[2], Lattice®, featuring its proprietary MIROR surface modification technology and self-expanding mechanical balloon delivery system, achieved a high rate of complete aneurysm occlusion while significantly reducing the in-stent stenosis (ISS) rate from 14.5% for conventional mainstream international devices to 1.8%. Meanwhile, the breakthrough innovation in its stent delivery system enables smoother navigation and more controlled deployment during the clinical treatment of intracranial aneurysms, substantially reducing procedural complexity for physicians and helping bring intracranial aneurysm treatment into a more streamlined and intuitive era.In the field of ischemic stroke, AccuMedical presented a comprehensive thrombectomy solution featuring the Grism® Stent Retriever with Dual Capture Tripods, Attractor® Aspiration Catheter, Cosine45 Micro Intermediate Catheter, and Sine21 Microcatheter. This powerful combination enables broader clinical applications. Among them, Grism® features a unique Stent Retriever with Dual Capture Tripods, incorporating a distal capture tripod with no tip, specialized flower-shaped clot trapping cells, and fully visible dual capture tripods. These features enable effective clot capture while maintaining vessel conformability and support thrombectomy for large vessel occlusion (LVO) and medium vessel occlusion (MeVO). Grism® delivers outstanding clot capture and anti-embolization performance. This integrated system significantly reduces procedural complexity and shortens critical rescue time, helping achieve rapid and effective revascularization for patients. <img src="/uploaded/accumedical/news/content/2026/09/21/dgfa02h5t38.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/dgfa02h5t38.png" style="width: 50%;">Products showcased by AccuMedical at the 21st China International Small and Medium Enterprises ExpoIn recent years, AccuMedical has continued to increase investment in R&amp;D and accelerate the translation of innovative achievements into clinical and commercial applications. A number of its technological breakthroughs and contributions to industrial development have received official recognition, with the company repeatedly earning prestigious national-level honors. The Lattice® Flow Diverter was recognized by NMPA as an “Innovative Medical Device” and was also recognized by the China National Intellectual Property Administration as a Patent-Intensive Product. The Lattice NEXT® Flow Diverter was selected for the 2025 First Batch of Major First-of-a-Kind Technical Equipment Catalogue of Beijing, released by the Beijing Municipal Commission of Development and Reform. It was also showcased as an innovative achievement in the biopharmaceutical sector at the 42nd National Pharmaceutical Industry Information Conference. The Lattice® series and Grism® Stent Retriever were both included in the Zhongguancun Innovative Medical Device Product Catalogue and received recognition under the Beijing New Technology, New Product and New Service program.AccuMedical’s participation in CISMEF marks an important opportunity to showcase its proprietary innovations and strengthen industry exchange and collaboration. Looking ahead, AccuMedical will continue to focus on unmet clinical needs in neurointervention, remain committed to proprietary innovation and international development, and accelerate the R&amp;D and adoption of innovative products. The company will contribute to improving the diagnosis and treatment of cerebrovascular diseases and bringing China’s high-end medical devices to the global market. References[1] Frost &amp; Sullivan, Industry Research Report on the Cerebrovascular Neurointerventional Medical Consumables Market.[2] Bao, L., He, S., &amp; Zhang, Y. (2026). Abstract DP322: Comparison of Lattice flow diverter and pipeline embolization device in Unruptured Intracranial Aneurysms: A Real-World, Propensity Score-Matching Study. Stroke, 57(Suppl_1). https://doi.org/10.1161/str.57.suppl_1.dp322

AccuMedical Showcases China’s Neurointervention Moment at the China International SME Expo

The HICOOL 2026 Global Entrepreneur Summit, themed “From the Source of Innovation to the Frontiers of Industry,” recently opened in Beijing. As an outstanding representative of Beijing’s innovation and entrepreneurship ecosystem, AccuMedical was invited to participate in the exhibition, presenting its key original innovations in the field of neurointervention. The company showcased full-stack neurointerventional solutions covering hemorrhagic stroke, ischemic stroke, and cerebrovascular access, highlighting the innovation capabilities of China’s high-end medical device industry. <img src="/uploaded/accumedical/news/content/2026/09/21/pwty3qz6qv.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/pwty3qz6qv.png" style="width: 50%;">AccuMedical Booth at HICOOL 2026Currently, China’s high-end medical device industry is entering a strategic period of accelerated development driven by favorable policies and increasing clinical demand. The 15th Five-Year Plan Outline identifies high-end medical devices as one of the key emerging industries and future growth sectors. The National Health Plan for the 15th Five-Year Period proposes comprehensive support for the development and application of innovative pharmaceuticals and medical devices, emphasizing stronger collaboration between medicine and engineering, as well as increased support for breakthroughs in core technologies, components, and complete systems of high-end medical devices. Driven by both policy support and market demand, China’s innovative pharmaceutical and medical device industry is undergoing a critical transition—from following global leaders to achieving parallel development, and in some areas, pursuing global leadership. At HICOOL 2026, AccuMedical’s showcased innovations attracted significant attention and recognition from visiting leaders. The company’s continuous breakthroughs in original core technologies and achievements in clinical translation were highly acknowledged, with encouragement to further strengthen research and development efforts in key technologies. 01 Innovation Breakthroughs Empower the Mission of Healthy ChinaOver the past decade, China’s medical device industry has faced challenges in many critical fields, with high-end products heavily dependent on imports and key technologies constrained by external suppliers. Since its establishment in 2017, AccuMedical has consistently focused on deep integration between clinical practice and engineering innovation, transforming unmet clinical needs into the starting point for research and development. Through original innovation, the company is committed to addressing clinical challenges and reducing dependence on imported technologies. To date, AccuMedical has received NMPA Class III medical device registrations for more than 10 innovative products, including the Lattice® Flow Diverter, Grism® Stent Retriever, Attractor® Aspiration Catheter, Cosine® Distal Access Catheter, and Sine® Microcatheter. <img src="/uploaded/accumedical/news/content/2026/09/21/6qcmihrxup7.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/6qcmihrxup7.png" style="width: 50%;">In the field of hemorrhagic stroke treatment, the Lattice® Flow Diverter integrates the world’s first mechanical balloon delivery system and MIROR surface modification technology, achieving comprehensive innovation across delivery, positioning, and deployment procedures. By transforming flow diverter implantation from an “experience-driven” procedure into a “technology-driven” approach, the product significantly improves procedural effectiveness and safety while reducing operational complexity. The second-generation Lattice NEXT® Flow Diverter further advances aneurysm treatment through its “zero-extension” distal guidewire design, helping move the procedure toward a more intuitive and simplified workflow. It further expands procedural accessibility beyond geographical limitations, enabling more patients in primary hospitals to benefit from advanced treatment options. <img src="/uploaded/accumedical/news/content/2026/09/21/jyvlo5skwob.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/jyvlo5skwob.png" style="width: 50%;">In the field of ischemic stroke treatment, the Grism® Stent Retriever features a globally unique fully radiopaque dual-capture claw design and a distal closed no-tip design. By enhancing clot capture efficiency, the device effectively addresses the challenge of clot escape during thrombectomy. More notably, its pre-market clinical study[1] &nbsp;expanded the therapeutic time window from the commonly applied 8-hour window to 24 hours, providing more patients with opportunities for timely treatment.From simplifying procedures to extending treatment windows, from filling technological gaps to achieving innovation leadership, AccuMedical leverages original innovation to advance the mission of Healthy China—making advanced medical technologies accessible beyond top-tier hospitals and accelerating their adoption in primary healthcare settings to benefit more patients. 02 From Chinese Original Innovation to Global SolutionsBuilding on its achievements in reducing reliance on imported technologies and advancing domestic innovation, AccuMedical is accelerating its global expansion by bringing Chinese original innovations to international markets. In 2026, both the Lattice® Flow Diverter and Grism® Stent Retriever obtained European Union MDR certification and CE marking, demonstrating that AccuMedical’s core products have met the highest European standards in quality management systems, clinical safety, and effectiveness, and are now eligible for market access across mainstream European healthcare markets. Previously, the Lattice® Flow Diverter, Attractor® Aspiration Catheter, and Sine® Microcatheter had obtained regulatory approvals in Vietnam and Indonesia, while the Cosine® Distal Access Catheter received clearance from the U.S. FDA. AccuMedical continues to expand its global market presence.In terms of academic influence, AccuMedical has also achieved a transition from “Chinese clinical data” to “international academic recognition.” Clinical research results involving core products such as the Lattice® Flow Diverter have been published in internationally recognized journals in the field of neurointervention, including Stroke, the Journal of NeuroInterventional Surgery (JNIS), and Frontiers in Neurology. Multiple clinical datasets have demonstrated performance exceeding that of comparable international products.During HICOOL 2026, global representatives from the medical industry, academic experts, and partners visited the AccuMedical booth to engage in in-depth discussions on the clinical data, procedural experience, and international regulatory progress of the company’s full-stack product portfolio. Visitors highly recognized the technological capabilities and innovation achievements of China’s original neurointerventional devices.From breaking away from imitation-based development and achieving domestic substitution, to delivering Chinese original solutions to global markets, AccuMedical is leveraging its continuously evolving full-stack product portfolio to advance the transformation of China’s high-end medical device industry—from the source of innovation to the forefront of global industry—under the guidance of the Healthy China strategy for the 15th Five-Year Period. [1]Grism Pre-market Clinical Study(GREAT-24)

Deepening Original Innovation, Advancing Toward Global Leadership: AccuMedical Showcases Full-Stack Neurointervention Solutions at HICOOL 2026

Recently, the Beijing Municipal Science &amp; Technology Commission and Zhongguancun Science Park Administrative Committee announced the list of projects granted Beijing New Technologies, New Products and New Services Recognition for 2026. Two innovative AccuMedical products—the Grism® Stent Retriever and the Lattice® NEXT Flow Diverter—received the recognition for their significant technological breakthroughs and their ability to drive industrial development. <img src="/uploaded/accumedical/news/content/2026/09/21/ws1bzzlzrv8.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/ws1bzzlzrv8.png" style="width: 50%;">On-site at Beijing New Technologies, New Products and New Services Launch EventThe Beijing New Technologies, New Products and New Services Recognition initiative focuses on emerging and future industries, key sectors, and areas where further development is urgently needed. It recognizes original and disruptive technological achievements that can help move emerging industries up the value chain, fill gaps in the domestic market, and demonstrate reliable quality and strong market potential.The recognition of these two products reflects the Beijing municipal authorities’ strong acknowledgement of AccuMedical’s innovative capabilities and technological leadership in the field of neurointerventional medical devices. The two products address the treatment of ischemic stroke and hemorrhagic cerebrovascular disease, respectively. Both meet pressing clinical needs and have already been introduced into clinical practice. <img src="/uploaded/accumedical/news/content/2026/09/21/873l9j4xuij.png" alt="" data-href="/uploaded/accumedical/news/content/2026/09/21/873l9j4xuij.png" style="width: 50%;">Exhibition of Beijing New Technologies, New Products and New Services Grism® Stent RetrieverEndovascular mechanical thrombectomy for acute ischemic stroke places extremely high demands on the clot-capturing capability and safety of thrombectomy stents.The Grism® Stent Retriever features the world’s first[1] fully radiopaque dual-capture basket, together with a closed distal-end, tipless design. During thrombectomy, this design enables effective clot capture while helping prevent the escape of clot fragments. The device also provides strong clot integration and precise intraprocedural positioning.The pre-market clinical study for grism® broke new ground by enrolling patients whose stroke onset occurred 8–24 hours before treatment. This forward-looking exploration of an extended treatment window may provide patients with ischemic stroke with better opportunities to receive treatment.In recognition of its outstanding innovation, the Grism® Stent Retriever has been included in the Zhongguancun Catalogue of Innovative Medical Device Products. Lattice® NEXT Flow DiverterThe Lattice® NEXT Flow Diverter incorporates a breakthrough distal guidewire design with no extended wire tip, together with an optimized stent delivery system. These innovations enable smoother device manipulation and more controlled deployment in the treatment of intracranial aneurysms, particularly in cases involving tortuous vessels.By substantially reducing the technical difficulty of device manipulation, Lattice® NEXT allows physicians to perform procedures with greater ease and confidence, helping usher intracranial aneurysm treatment into an era of “automatic-mode” operation.In 2025, Lattice® NEXT was included in the First Batch of the Beijing 2025 Catalogue of First-of-Its-Kind Major Technical Equipment. It was also prominently showcased as an innovative achievement in the biopharmaceutical sector at the 42nd National Pharmaceutical Industry Information Annual Conference.The recognition is jointly conferred by five municipal government authorities: the Beijing Municipal Science &amp; Technology Commission and Zhongguancun Science Park Administrative Committee, the Beijing Municipal Commission of Development and Reform, the Beijing Municipal Bureau of Economy and Information Technology, the Beijing Municipal Commission of Housing and Urban-Rural Development, and the Beijing Municipal Administration for Market Regulation. It is therefore a highly authoritative municipal-level recognition.Recognized new technologies, products, and services may benefit from policy support in areas such as government procurement, promotion, and application. AccuMedical’s Lattice® Flow Diverter and Cosine®45 Distal Access Catheter previously received the same recognition.As an innovation pioneer dedicated to the field of neurointervention, AccuMedical has remained committed to original innovation and has embedded self-reliance and strength in science and technology into its corporate DNA. Leveraging Beijing’s well-developed innovation ecosystem, the company promotes the deep integration of industry, academia, research, and application. Through a series of independently developed breakthrough technologies and products, AccuMedical is filling gaps in the industry and accelerating the domestic development and adoption of high-end neurointerventional medical devices.Looking ahead, AccuMedical will align closely with the goals of China’s 15th Five-Year Plan, focus on new quality productive forces and the strategic emerging biopharmaceutical industry, and continue to pursue breakthroughs in key core technologies. Through independent innovation, the company will remain committed to safeguarding patients’ lives and health and contributing to higher standards of diagnosis and treatment for cerebrovascular diseases in China. [1]As of August 22, 2025

Two More Innovative AccuMedical Products Receive Beijing Recognition for New Technologies, New Products and New Services

<img src="/uploaded/accumedical/news/content/2026/07/03/81ubv134y6x.png" alt="" data-href="/uploaded/accumedical/news/content/2026/07/03/81ubv134y6x.png" style="width: 50%;">Recently, two original products developed by AccuMedical—the Lattice® Flow Diverter and the Grism® Stent Retriever—officially obtained EU MDR CE Mark certification. This signifies that the Company's solutions for hemorrhagic stroke and ischemic stroke have simultaneously gained access to the European Union market, representing a milestone of great significance for its international development.The European Union Medical Device Regulation (EU MDR 2017/745) is one of the world's most stringent regulatory frameworks governing medical devices. The simultaneous certification of these two products fully demonstrates that AccuMedical's product design, clinical value, and quality management system comply with the regulatory requirements of the European Union, and that its innovation capabilities have been recognized by internationally authoritative regulatory authorities. At the same time, the value of CE certification extends far beyond access to the European market alone——Through cross-border regulatory recognition mechanisms, local registration procedures in multiple regions, including Southeast Asia, the Middle East, Africa, and Latin America, can be significantly simplified, substantially improving overseas market access efficiency and providing strong momentum for the Company's global commercialization.The certified products include:Lattice® Flow Diverter, which is primarily indicated for the treatment of intracranial aneurysms. Incorporating AccuMedical's original mechanical balloon delivery system and MIROR surface modification technology, the product was approved for marketing through the NMPA Innovative Medical Device Special Review Procedure (Green Channel) in October 2022. It subsequently received regulatory approval in Vietnam in 2025 and Indonesia in 2026. Grism® Stent Retriever, which is indicated for the treatment of acute ischemic stroke. Its unique distal closed no-tip design effectively prevents clot escape, improves the first-pass recanalization rate, and helps secure valuable treatment time for patients. The product was approved for marketing by the NMPA in 2025. Together, these two products respectively address the therapeutic areas of hemorrhagic stroke and ischemic stroke, further strengthening AccuMedical's foundation for global development while providing high-quality China Solutions for patients worldwide.

EU MDR CE Certification Secured | AccuMedical's Hemorrhagic and Ischemic Stroke Products Approved Simultaneously

Today, the 28th China Beijing International High-Tech Expo (“CHITEC”) officially opened in Beijing, comprehensively showcasing China’s cutting-edge technological and innovative achievements across frontier technologies, emerging industries, future industries, and other related fields. As an outstanding innovative enterprise in the field of neurointervention, AccuMedical Beijing Inc.(hereinafter referred to as “AccuMedical”) was invited to participate in the exhibition, systematically presenting its “full-stack neurointerventional solutions” centered on the diagnosis and treatment of hemorrhagic and ischemic stroke, as well as cerebrovascular access systems. <img src="/uploaded/accumedical/news/content/2026/05/22/wdkxnzzaond.png" alt="" data-href="/uploaded/accumedical/news/content/2026/05/22/wdkxnzzaond.png" style="width: 50%;">During the exhibition, AccuMedical’s two latest independently developed treatment solutions attracted significant attention. For the treatment of acute ischemic stroke (AIS, also known as cerebral infarction), AccuMedical introduced an integrated vascular recanalization solution centered on the Grism® Stent Retriever, featuring coordinated compatibility with multiple devices to provide clinicians with a safer and more efficient recanalization option. Addressing the current clinical challenge that chronic/subacute subdural hematoma can only be treated through surgical intervention and lacks minimally invasive treatment options, AccuMedical’s innovative product, the Coincide® Liquid Embolic System , is expected to fill this procedural gap.<img src="/uploaded/accumedical/news/content/2026/05/22/f1p6dya30zg.png" alt="" data-href="/uploaded/accumedical/news/content/2026/05/22/f1p6dya30zg.png" style="width: 50%;"><img src="/uploaded/accumedical/news/content/2026/05/22/gya8nmh3m9.png" alt="" data-href="/uploaded/accumedical/news/content/2026/05/22/gya8nmh3m9.png" style="width: 50%;">(AccuMedical booth at the Beijing International High-Tech Expo)Full-Stack Synergy: Grism® Integrated Recanalization Solution Addresses the Challenge of Clot Fragment Escape During Thrombectomy <img src="/uploaded/accumedical/news/content/2026/05/22/tsvei71gvhp.png" alt="" data-href="/uploaded/accumedical/news/content/2026/05/22/tsvei71gvhp.png" style="width: 50%;">(AccuMedical Integrated Recanalization Solution for Acute Ischemic Stroke)Acute ischemic stroke is highly prevalent in China, while the therapeutic window for intervention remains limited Conventional thrombectomy procedures continue to face major clinical challenges, including thrombus fragmentation leading to distal embolic escape and re-embolization, as well as difficulties in navigating tortuous vasculature that prolong procedural time, all of which present significant challenges for neurointerventional physicians. AccuMedical’s integrated recanalization solution for acute ischemic stroke, centered on the Grism® Stent Retriever, achieves coordinated compatibility among multiple original devices, enabling a “one-stop” procedural design spanning vascular access establishment, thrombus retrieval, and distal embolic protection. The solution provides seamless procedural integration and smooth device operability, significantly improving vascular recanalization efficiency [1].As the core component of the solution, the Grism® Stent Retriever features the world’s first fully radiopaque dual capture tripods and a distal closed no-tip design [2], enabling effective thrombus capture while preventing clot fragment escape. Particularly noteworthy is that the product’s pre-market clinical study, Grism Recanalization Device for Endovascular Treatment of Acute Ischemic Stroke within 24 hours (GREAT-24), breakthroughly expanded the enrollment treatment window from the conventional 8 hours to 24 hours. Moreover, 37% of enrolled patients were late-window patients treated within 8–24 hours after stroke onset. This forward-looking exploration of expanded treatment windows is expected to provide acute ischemic stroke patients with improved treatment opportunities.In recognition of its outstanding innovation, the Grism® Stent Retriever has been included in the Zhongguancun Innovative Medical Device Product Catalog.To further ensure smooth procedural performance, the solution also integrates the Attractor® Intracranial Aspiration Catheter, featuring excellent aspiration capability; the Cosine® 45 Distal Access Catheter, capable of establishing stable intracranial support access; and the Sine® 21 Microcatheter, which demonstrates excellent trackability and compliance within delicate and tortuous cerebral vasculature. The full-stack product portfolio demonstrates outstanding system synergy in complex tortuous vessels, providing more valuable opportunities for patient rescue and neurological function recovery.Forward-Looking Pipeline Strategy: Original Innovation in Liquid Embolic Systems Expected to Fill Domestic Interventional Treatment Gap <img src="/uploaded/accumedical/news/content/2026/05/22/32u2v3058oc.png" alt="" data-href="/uploaded/accumedical/news/content/2026/05/22/32u2v3058oc.png" style="width: 50%;">(AccuMedical investigational product: Coincide® Liquid Embolic System)At this year’s Beijing International High-Tech Expo, AccuMedical also showcased its key investigational product, the Coincide® Liquid Embolic System. The product is primarily intended for the treatment of chronic/subacute subdural hematoma and is currently in the clinical trial stage. At present, the disease is primarily treated through surgical procedures in China, with no dedicated interventional treatment solution available. Following commercialization, Coincide® is expected to fill this domestic gap by providing patients with a more minimally invasive and precise treatment option.The research and development project was included in the Beijing Municipal Science and Technology Program for the Cultivation of Innovative Pharmaceutical Products and Platforms in 2025.From the innovation leadership of the Lattice® Flow Diverter series, to the frontier exploration represented by the Grism® Stent Retriever, and further to original breakthroughs in liquid embolic agents, AccuMedical is accelerating its transformation into a comprehensive industry leader across the full neurointerventional landscape.Leveraging its efficient R&amp;D translation capabilities and global operational system, the company has established a tiered growth-driving structure characterized by “commercialized products consolidating scale, core second-tier pipelines driving growth momentum, and reserve pipelines strategically positioning future opportunities.” While providing momentum for the high-quality growth of China’s innovative medical device industry, AccuMedical is also contributing “China Solutions” to global cerebrovascular health. Notes[1] Results from the pre-market clinical study Grism Recanalization Device for EndovAscular Treatment of Acute Ischemic Stroke within 24 hours (GREAT-24) demonstrated that the first-pass recanalization rate of the Grism treatment group reached 58.6%, compared with 48.5% in the control group.[2] As of August 22, 2025.

AccuMedical Showcases at the 2026 Beijing International High-Tech Expo: Expanding the Boundaries of Neurointerventional Treatment with an Original Innovation Product Portfolio

During the 2026 Zhongguancun Forum Annual Conference, Xinhua News Agency conducted an on site visit to the AccuMedical exhibition booth and invited the Founder and Chief Executive Officer of AccuMedical, Yi Ran Lv, for a feature interview to present to the global audience the “Chinese Precision” in the field of neurointervention. <img src="/uploaded/accumedical/news/content/2026/04/16/19r370r5oro.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/19r370r5oro.png" style="width: 50%;">The visit report was published on Xinhua News App, as well as Xinhua’s Facebook, YouTube, and X accounts. <img src="/uploaded/accumedical/news/content/2026/04/16/qr9yct2u8b.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/qr9yct2u8b.png" style="width: 50%;">01 In Depth Dialogue: From “Accu” to AccuMedical’s Original AspirationIn the interview, CEO Yi Ran Lv deeply articulated the brand philosophy. The English name “AccuMedical”—derived from “Accurate”—is not merely a name, but a reflection of the company’s pursuit of precision in every surgery, every vascular pathway, and every micron level manipulation. “Neurointerventional procedures demand near exacting precision,” Lv explained, “and our mission is to transform high risk traditional surgeries into safer, more efficient minimally invasive solutions through continuous innovation.”<img src="/uploaded/accumedical/news/content/2026/04/16/0hj2nrfov4s.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/0hj2nrfov4s.png" style="width: 50%;">02 Hard Core Demonstration: Full Stack Neurointervention SolutionsThrough an on site demonstration, Yi Ran Lv shared the outstanding performance of AccuMedical’s products:“For cerebrovascular diseases, which are highly prevalent among Chinese and other Asian populations, AccuMedical is enhancing the safety and effectiveness of procedures through designs that better address clinical pain points.” <img src="/uploaded/accumedical/news/content/2026/04/16/iy8nzyfrqhp.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/iy8nzyfrqhp.png" style="width: 50%;">03 Data Led Leadership: Outstanding Clinical Performance MetricsClinical data serve as the ultimate benchmark of product capability. During the interview, Lv shared the latest scientific findings on the Lattice® Flow Diverter. “According to the latest literature[1], while maintaining excellent complete occlusion rates, the in stent stenosis (ISS) of the Lattice® Flow Diverter has dropped to 1.8% , a rate far below the 14.5% reported for conventional international devices, reaching a world leading level.”Having participated in the Zhongguancun Forum for three consecutive years, AccuMedical has grown increasingly resolute in its path. We are not only intensively advancing research and development, tackling multiple core underlying technologies such as stent delivery system architecture and surface material modification, but also committed to promoting the “China Standard” on a global scale.Guided by its founding principle of “Precise, Treat as Our Own,” AccuMedical will continue to push the boundaries of complex procedure technologies with innovation, further safeguard life.<a href="https://mp.weixin.qq.com/s/1VvHcLC2jU_V-J9XJPgjXA" target="_blank">（Click to watch the video）</a>References:[1]: Bao, L., He, S., &amp; Zhang, Y. (2026). Abstract DP322: Comparison of Lattice flow diverter and pipeline embolization device in Unruptured Intracranial Aneurysms: A Real-World, Propensity Score-Matching Study. Stroke, 57(Suppl_1). https://doi.org/10.1161/str.57.suppl_1.dp322

Authoritative Spotlight | Xinhua Interview with AccuMedical: Showcasing China’s Neurointervention Strength to the World

(March 25, 2026, Beijing) — Today, the 2026 Zhongguancun Forum Annual Conference, themed “Deep Integration of Technological Innovation and Industrial Innovation,” grandly opened. As an innovative company dedicated to the field of neurointervention, AccuMedical presented its comprehensive neurointervention portfolio at the permanent exhibition. This marks the third consecutive year that AccuMedical has been invited to participate. Over the past three years, the company has forged ahead with determination, evolving from a rising technology player with a single flagship product into an industry pioneer offering comprehensive solutions that cover both hemorrhagic and ischemic stroke, as well as access systems for cerebrovascular interventions. Leveraging its strong foundation in original innovation and upholding its commitment to “true innovation for real-world application,” AccuMedical is driving transformation through a dual-engine strategy: enabling comprehensive procedural innovation and continuously developing blockbuster products. The company is becoming a key force in propelling China’s high-end medical devices onto the global stage.Lv Yiran, Founder and CEO of AccuMedical, stated: “Guided by the national strategies of building a ‘Healthy China’ and fostering ‘new quality productive forces,’ China’s medical device industry is achieving breakthroughs through foundational technological innovation. As a primary driver of innovation, enterprises must take on the responsibility of deeply integrating the innovation chain with the industrial chain. AccuMedical has consistently adhered to deep ‘clinician-engineer collaboration,’ transforming clinical pain points into engineering starting points for product development, and using the improvement of patients’ quality of life as the ultimate benchmark for innovation. Through the Zhongguancun Forum, we will continue to advance from ‘domestic substitution’ to ‘global leadership,’ supporting the development of an accessible cerebrovascular disease diagnosis and treatment system with high-quality original innovations, while establishing a global benchmark for China’s ‘new quality productive forces.’” <img src="/uploaded/accumedical/news/content/2026/04/09/qyhh1k2b1w.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/09/qyhh1k2b1w.png" style="width: 50%;">(AccuMedical’s booth is located in the High-End Medical Device Exhibition Area of the Zhongguancun Forum permanent exhibition)Highlights of the AccuMedical Booth:When micron-level intelligent manufacturing meets life sciences, innovation is redefining the upper limits of cerebrovascular disease treatment. Over the past three years, the Zhongguancun Forum has witnessed AccuMedical’s leap from single-product breakthroughs to comprehensive technological innovation. At this year’s exhibition, the debut of its “comprehensive neurointervention portfolio” includes solutions for hemorrhagic stroke, ischemic stroke, and access products. With a high-quality portfolio of original innovations, AccuMedical is empowering procedural innovation and transformation across the board: <img src="/uploaded/accumedical/news/content/2026/04/09/1w1d2eaa8hs.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/09/1w1d2eaa8hs.png" style="width: 50%;">Hemorrhagic Stroke – Highly Effective Solutions: For the treatment of intracranial aneurysms, often referred to as “time bombs,” AccuMedical showcased its highly anticipated Lattice® series Flow Diverters. According to the latest real-world study presented at the 2026 International Stroke Conference (ISC) of the American Stroke Association (ASA), Lattice®—featuring its proprietary MIROR surface modification technology and self-expanding mechanical balloon delivery system—maintains excellent complete occlusion rates while significantly reducing in-stent stenosis (ISS) to 1.8%,a rate far below the 14.5% reported for conventional international devices. These authoritative clinical data demonstrate the substantial benefits of original innovation for patient outcomes and mark AccuMedical’s transition from “substitution” to “leadership,” with key performance metrics now surpassing international brands. <img src="/uploaded/accumedical/news/content/2026/04/09/vewabskq9r.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/09/vewabskq9r.png" style="width: 50%;">Ischemic Stroke – Rapid Recanalization of the Life Pathway: In acute ischemic stroke rescue, “time is life,” and efficient, safe thrombectomy tools are critical. AccuMedical presented a suite of thrombectomy products, including the Grism® Stent Retriever with Dual Capture Tripods, Attractor® Aspiration Catheter, Cosine45 Micro Intermediate Catheter, and Sine21 Microcatheter. This powerful combination enables broader clinical applications. Among them, Grism® features a unique Stent Retriever with Dual Capture Tripods that includes a distal capture tripod with no tip, specialized flower-shaped clot trapping cells, and fully visible dual capture tripods, delivering outstanding clot capture and anti-embolization performance. This design significantly reduces procedural complexity and shortens critical rescue time, ensuring rapid and effective revascularization for patients. <img src="/uploaded/accumedical/news/content/2026/04/09/ch37jeqcug.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/09/ch37jeqcug.png" style="width: 50%;">Full-Scenario Access Device Support: Precise access to the lesion is fundamental to the success of neurointerventional procedures. In addition to the Sine® microcatheter series and Cosine® distal access catheter series, AccuMedical highlighted its Paracurve® Radial Access Guiding Catheter, which leads the trend in minimally invasive approaches. Compared with traditional femoral access, the radial approach offers a shorter access path, significantly reducing procedure time and securing valuable golden rescue windows for patients. It is also less invasive and eliminates the need for prolonged bed rest, greatly improving postoperative experience. <img src="/uploaded/accumedical/news/content/2026/04/09/bnoznt6v9ks.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/09/bnoznt6v9ks.png" style="width: 50%;">(AccuMedical Neurointervention Product Portfolio)AccuMedical implements technological self-reliance and strength across every stage of R&amp;D. Addressing key clinical challenges—such as the heavy reliance on physician experience in neurointervention and the steep learning curve at primary care levels—the company continues to achieve breakthroughs in core underlying technologies, significantly lowering procedural barriers and accelerating the accessibility of advanced medical technologies at the grassroots level. From breaking away from the traditional path of “imitation and following” in domestic substitution to exporting China-originated solutions globally, AccuMedical is building an ever-evolving full-stack product portfolio, contributing indispensable Chinese strength to the global advancement of cerebrovascular disease diagnosis and treatment.

“China-Originated Innovation, Manufacturing Brilliance for the World!” AccuMedical Showcases Its Comprehensive Neurointervention Portfolio at the Zhongguancun Forum Once Again

Recently, AccuMedical Inc. (hereinafter referred to as “AccuMedical”) was officially recognized as a Beijing Intellectual Property Advantage Unit by the Beijing Intellectual Property Office, in light of its outstanding performance in intellectual property creation, utilization, management, and protection. This authoritative recognition signifies that AccuMedical’s innovative capabilities and systematic intellectual property strategy in the field of neurointervention have received high-level official acknowledgment. <img src="/uploaded/accumedical/news/content/2026/04/16/j6o8jcohy8g.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/j6o8jcohy8g.png" style="width: 50%;"><img src="/uploaded/accumedical/news/content/2026/04/16/kcn10x5htdp.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/kcn10x5htdp.png" style="width: 50%;">As an innovative medical device enterprise in neurointervention, AccuMedical has always regarded technological innovation as its core engine for development. By integrating top-tier interdisciplinary teams, the company has established a comprehensive R&amp;D system, overcoming and mastering the core design, development, and manufacturing technologies of neurointerventional devices, while independently researching and developing multiple core technologies. To date, the company has applied for 157 domestic and international patents, building a solid technological barrier.AccuMedical’s core product, the Lattice® Flow Diverter, embodies the company’s innovation capabilities. Recognized by the NMPA as an Innovative Medical Device, the product leverages original designs such as a mechanical balloon delivery system and MIROR surface modification technology, achieving breakthroughs in effectiveness, safety, and procedural convenience, and breaking away from the long-standing “follow-and-copy” path of domestic enterprises.From being recognized in 2022 as a Beijing Intellectual Property Pilot Unit to the current upgrade as a Beijing Intellectual Property Advantage Unit, AccuMedical will benefit from enhanced policy support and resource prioritization, facilitating faster translation and application of technological achievements. AccuMedical will continue to deepen its intellectual property strategy, empowering product innovation with high-value patents, and providing better diagnostic and therapeutic solutions for neurovascular patients and physicians worldwide.

AccuMedical Recognized as a Beijing Intellectual Property Advantage Unit, Cementing Its Leadership in Neurointervention Through Innovative Strength

On November 6, 2025, Cui Xiaohao, Deputy Secretary of the CPC Shunyi District Committee, Secretary of the Party Leadership Group and Mayor of the Shunyi District Government, Deputy Secretary of the Working Committee of the Capital International Airport Economic Zone, and Director of the Administrative Committee of the Capital International Airport Economic Zone, visited AccuMedical Inc. (hereinafter “AccuMedical” or “we”) to conduct an in-depth research and exchange session. Centering on the theme of “Implementing the spirit of the Fourth Plenary Session of the 20th CPC Central Committee and accelerating the construction of a modern industrial system,” the visit aimed to promote the high-quality development of Shunyi District’s pharmaceutical and healthcare industries, identify enterprise needs, and empower industrial growth with precision. <img src="/uploaded/accumedical/news/content/2025/11/14/kzk5m53t0sn.png" alt="" data-href="/uploaded/accumedical/news/content/2025/11/14/kzk5m53t0sn.png" style="width: 972.99px;height: 709.54px;">Listening to AccuMedical’s Development Overview During the visit, District Mayor Cui and his delegation toured AccuMedical’s product showroom and production workshop, gaining detailed insights into the company’s core product R&amp;D, manufacturing processes, market expansion strategies, and future development plans.Cui emphasized that enterprises should leverage their professional strengths, focus on specialized segments within the pharmaceutical and healthcare sectors, continuously optimize management models, strengthen market research and analysis, enhance technological innovation and R&amp;D investment, and expand their market presence. He encouraged AccuMedical to maintain its strong growth momentum, play a leading and demonstrative role, and drive the overall advancement of the industrial chain.AccuMedical CEO noted that technological advancement is the core competitiveness of the medical device industry. Since its founding, AccuMedical has focused on breakthroughs and improvements in key technologies and processes, with the goal of addressing unmet clinical needs. AccuMedical will continue to increase our R&amp;D investment, refine product processes, and optimize our portfolio based on market demand in the future. Through continuous technological iteration and industrial chain collaboration, the company aim to deliver safer and more efficient clinical solutions, contributing to the high-quality development of the healthcare industry.AccuMedical Inc. is an innovative medical device company specializing in neurointervention. Its product portfolio covers devices for hemorrhagic and ischemic stroke treatment as well as auxiliary access products, providing comprehensive solutions for clinical departments treating cerebrovascular diseases. Through independent R&amp;D, AccuMedical has achieved groundbreaking innovations in multiple fields, including stent delivery systems, stent braiding, laser cutting, material surface modification, multi-segment variable-stiffness polymers, and liquid embolic polymers. Many of these innovations have been successfully transformed into core technologies with industry-leading advantages. Among its flagship products, Lattice Flow Diverter stands out for its unique technical features and innovative design, accelerating the quality improvement and localization of neurointerventional devices and bridging multiple technological gaps in China’s medical device industry.

Cui Xiaohao, Mayor of the Shunyi District Government, Visits AccuMedical to Boost High-Quality Development

On August 22, AccuMedical’s grism® Distal Closed Intracranial Thrombectomy Stent was successfully approved for registration by the National Medical Products Administration (NMPA). Registration Certificate Number: NMPA 20253031621.<img src="/uploaded/accumedical/news/content/2026/04/16/s3n56ckg8gd.png" alt="" data-href="/uploaded/accumedical/news/content/2026/04/16/s3n56ckg8gd.png" style="width: 50%;">The grism® Distal Closed Intracranial Thrombectomy Stent is primarily used for the treatment of ischemic stroke. After being delivered through the arterial pathway to the site of intracranial thromboembolism, the stent self-expands to establish an immediate blood flow channel, allowing penumbral brain cells to be reperfused. The stent is then retracted to capture and remove the thrombus, restoring cerebral blood flow and perfusion, thereby reducing mortality and disability rates.The grism® stent features a globally unique and innovative multifunctional radiopaque claw design, a closed atraumatic tip, a flower-pattern mesh structure, and advanced surface treatment technology. It can be delivered through small-size microcatheters and is available in a broader range of models and sizes. During clinical procedures, the device demonstrates excellent thrombus integration, strong clot capture capability, low risk of clot fragmentation and escape, and high precision in intraoperative positioning.To date, AccuMedical has obtained NMPA approvals for more than 10 innovative products, including Lattice®, Lattice® NEXT, attractor®, cosine®, sine®, achieving full coverage of neurointervention scenarios for hemorrhagic stroke, ischemic stroke, and access support. The company has filed 135 patent applications, 76 of which have been granted, forming a robust and high-barrier intellectual property portfolio.As one of the key drafting units of the national industry standard for neurovascular thrombectomy stents, AccuMedical actively participates in the standardization of medical device evaluation in China, continuously promoting improvements in industry quality. Leveraging its innovation strength and industrialization achievements, the company has been recognized as a National High-Tech Enterprise in 2023 and a National-level “Little Giant” Enterprise in 2024.

Exciting News! AccuMedical’s grism® Distal Closed Intracranial Thrombectomy Stent Approved for Marketing!